Business Context and Reporting Period
This Form 8-K is a current report filed by NantKwest, Inc. (not Immunitybio, Inc.) on June 19, 2020, covering events occurring on June 16 and June 18, 2020. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol NK.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and legal amendments rather than financial performance.
Material Changes
- Board Departure: On June 16, 2020, Steve Gorlin resigned from the Board of Directors effective immediately. The resignation was for personal reasons and was not the result of any disagreement with the Company regarding operations, policies, or practices.
- Bylaw Amendment: On June 18, 2020, the Board approved amended and restated bylaws adding an "Exclusive Forum" provision. This designates the federal district courts of the United States as the exclusive forum for complaints arising under the Securities Act of 1933, unless the Company consents in writing to an alternative forum.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The primary risk disclosed relates to the change in the exclusive forum for securities litigation, which may limit the ability of shareholders to bring claims in state courts or other jurisdictions.
Investor Verification Checklist
- Verify the identity of the registrant (NantKwest, Inc.) versus the metadata label (Immunitybio, Inc.).
- Confirm the effective date of Steve Gorlin's resignation and the composition of the Board post-departure.
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.1) to understand the scope of the exclusive forum provision.
- Check subsequent filings for any impact of the board change on company strategy or operations.